Lipoprotein associated phospholipase A2 concentration predicts total and cardiovascular mortality independently of established risk factors (The Ludwigshafen Risk and Cardiovascular Health Study)

Clinical Laboratory

Volumn 57, Issue 9-10, 2011, Pages 659-667

  Kleber, Marcus E ^a   Wolfert, Robert L ^b   De Moissl, Graciela Delgado ^c   Grammer, Tanja B ^d   Dietz, Simone ^d   Winkelmann, Bernhard R ^e   Boehm, Bernhard O ^f   Mar̈z, Winfried ^c,d  

^a LURIC Study Nonprofit LLC   (Germany)

^b diaDexus Inc   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d SYNLAB ACADEMY   (Germany)

^e Cardiology Group   (Germany)

^f UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

C reactive protein: (CRP); Coronary artery disease: (CAD); Lipoprotein associated phospholipase A2: (LpPLA2); Platelet activating factor acetyl hydrolase: (PAF AH)

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATION; PREDICTION; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; AREA UNDER CURVE; CORONARY DISEASE; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; ROC CURVE; SURVIVAL RATE;

EID: 80054779670     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Itabe H. Oxidized phospholipids as a new landmark in atherosclerosis. Prog Lipid Res 1998;37:181-207. (Pubitemid 28391411)
2. Stafforini DM. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther 2009;23:73-83.
3. Macphee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999;338(Pt 2):479-87.
4. Karabina SA, Elisaf M, Bairaktari E, Tzallas C, Siamopoulos KC, Tselepis AD. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Invest 1997;27:595-602. (Pubitemid 27320037)
5. Lavi S, McConnell JP, Rihal CS, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007;115:2715-21. (Pubitemid 46842787)
6. Imaizumi TA, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, Zimmerman GA. Platelet-activating factor: a mediator for clinicians. J Intern Med 1995;238:5-20.
7. Evangelou AM. Platelet-activating factor (PAF): implications for coronary heart and vascular diseases. Prostaglandins Leukot Essent Fatty Acids 1994;50:1-28. (Pubitemid 24024357)
8. Karabina SA, Ninio E. Plasma PAF-acetylhydrolase: An unfulfilled promise? Biochim Biophys Acta 2006;1761:1351-8.
9. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 2008101:41F-50F.
10. Koenig W, Khuseyinova N. Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther 2009;23:85-92.
11. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2004;109:837-42. (Pubitemid 38252734)
12. Winkler K, Winkelmann BR, Scharnagl H, et al. Platelet-Activating Factor Acetylhydrolase Activity Indicates Angiographic Coronary Artery Disease Independently of Systemic Inflammation and Other Risk Factors. The Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2005;111:980-7. (Pubitemid 40354515)
13. Winkler K, Hoffmann MM, Winkelmann BR, et al. Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen Risk and Cardiovascular Health Study). Clin Chem 2007;53:1440-7. (Pubitemid 47206339)
14. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006;26:1586-93. (Pubitemid 44288987)
15. Winkelmann BR, Marz W, Boehm BO, et al. Rationale and design of the LURIC study-a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001;2:S1-73.
16. Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coronary artery disease. Report of the ad hoc committee for grading of coronary artery disease. Circulation 1975;50(Suppl5):7-40.
17. Association AD. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
18. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005;165:2479-84. (Pubitemid 41720009)
19. Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005;111:570-5. (Pubitemid 40216483)
20. Kim JY, Hyun YJ, Jang Y, et al. Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study. Am J Clin Nutr 2008;88:630-7.
21. Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148-55.
22. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005;51:2264-73. (Pubitemid 41692569)
23. Stafforini DM, Carter ME, Zimmerman GA, McIntyre TM, Prescott SM. Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma. Proc Natl Acad Sci U S A 1989;86:2393-7. (Pubitemid 19102515)
24. Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009;1791:327-38.
25. Blencowe C, Hermetter A, Kostner GM, Deigner HP. Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein. J Biol Chem 1995;270:31151-7. (Pubitemid 26018396)
26. Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007;27:2094-9. (Pubitemid 350287235)
27. Tsironis LD, Katsouras CS, Lourida ES, et al. Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. Atherosclerosis 2004;177:193-201. (Pubitemid 39361156)